GenPhar

GenPhar was a biopharmaceutical company based in South Carolina that specialized in the development of genetic vaccines for infectious diseases and biodefense. The company utilized a proprietary multivalent adenovirus vector platform designed to express multiple antigens, aiming to provide broad protection against various viral strains and pathogens. Their pipeline included candidates for high-priority threats such as Ebola, Marburg, and Lassa fever, as well as chronic infections like Hepatitis B and HIV. GenPhar received significant funding from federal agencies, including the NIH and the Department of Defense, to advance its biodefense programs. However, the company ceased operations following legal and financial complications involving the management of federal research grants. At its peak, GenPhar was a notable player in the development of rapid-response vaccine technologies for emerging viral threats.